An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

NCT03414983 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: Nivolumab
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: Fluorouracil
DRUG: Bevacizumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]